Supporting evidence for these observations came from independent data analysis of published RNA-seq datasets, which contained significantly larger patient cohorts, showing that SRPX is significantly upregulated in glioblastomas compared to normal brain tissues and lower grade gliomas (Figure 2 and Figure 3) and suggesting that SRPX serves as a tumor marker only in glioblastomas. This evidence concerns the gene SRPX and central nervous system cancer.